Albumin therapy for hepatic encephalopathy: current evidence and controversies.
Metab Brain Dis
; 38(5): 1759-1763, 2023 06.
Article
em En
| MEDLINE
| ID: mdl-35616800
ABSTRACT
Hepatic encephalopathy (HE) is a common complication that occurs in 16-21% of end-stage cirrhosis patients. Emerging evidence suggests that systemic inflammation and oxidative stress may play a role in the development of HE. Recent understanding on the anti-inflammatory properties of human albumin has led to growing interest of using human albumin for the treatment and prevention of HE among decompensated patients. In this review, we aim to discuss the current evidence and controversies of using human albumin for the treatment and prevention of HE in advanced cirrhosis patients.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Encefalopatia Hepática
Limite:
Humans
Idioma:
En
Revista:
Metab Brain Dis
Assunto da revista:
CEREBRO
/
METABOLISMO
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Singapura